While both insulin and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have proven effective in glycemic control for T2DM, insulin use carries the risk of hypoglycemia [9]. The gene discussed is INS; the disease is type 2 diabetes mellitus.